Cimeio Therapeutics Announces Poster Presentations at ASH 2023
- CD45 ADC effectively eliminates AML cells in vivo, while CD45 epitope-edited healthy cells were shielded from ADC depletion -BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company that is the leader of the field of epitope editing, today announced the acceptance of two...
San Diego United States San Diego Convention Center Thomas Fuchs San Diego Convention Center Halls Hspcs Are
Source: pharmiweb.com